Abstract
BackgroundColorectal cancer (CRC) survivors are known to experience various symptoms that significantly affect their quality of life (QOL); therefore, it is important to identify clinical markers related with CRC survivor QOL. Here we investigated the relationship between serum chemerin levels, a newly identified proinflammatory adipokine, and QOL in CRC survivors.MethodsA data of total of 110 CRC survivors were analysed in the study. Serum chemerin levels were measured with an enzyme immunoassay analyser. Functional Assessment of Cancer Therapy (FACT) scores were used as an indicator of QOL in CRC survivors.ResultsWeak but not negligible relationships were observed between serum chemerin levels and FACT-General (G) (r = -0.22, p<0.02), FACT-Colorectal cancer (C) (r = -0.23, p<0.02) and FACT-Fatigue (F) scores (r = -0.27, p<0.01) after adjusting for confounding factors. Both stepwise and enter method multiple linear regression analyses confirmed that serum chemerin levels were independently associated with FACT-G (stepwise: β = -0.15, p<0.01; enter: β = -0.12, p = 0.02), FACT-C (stepwise: β = -0.19, p<0.01; enter; β = -0.14, p = 0.02) and FACT-F scores (stepwise: β = -0.23, p<0.01; enter: β = -0.20, p<0.01).ConclusionsOur results demonstrate a weak inverse relationship between serum chemerin and CRC survivor QOL. Although it is impossible to determine causality, our findings suggest that serum chemerin levels may have a significant association with CRC survivor QOL. Further prospective studies are required to confirm the clinical significance of our pilot study.
Highlights
Colorectal cancer (CRC) is one of the most common cancers worldwide [1]
Weak but not negligible relationships were observed between serum chemerin levels and Functional Assessment of Cancer Therapy (FACT)-General (G) (r = -0.22, p
Both stepwise and enter method multiple linear regression analyses confirmed that serum chemerin levels were independently associated with FACT-G, FACT-C and FACT-F scores
Summary
Colorectal cancer (CRC) is one of the most common cancers worldwide [1]. The survival rate of CRC patients has steadily improved in large part due to the increased rate of early detection and more effective treatments [2]. CRC survivors are known to suffer from various symptoms, including chronic bowel irritability and cancer-related fatigue that significantly affect their quality of life (QOL) [3]. Long-term care that improves QOL in CRC survivors is considered important. The identification of clinical markers and biomarkers that allow clinicians to predict the QOL of CRC survivors are needed. In previous studies, increased cytokine levels in cancer patients were significantly associated with non-specific chronic symptoms, such as fatigue, cognitive changes, and depressed mood [4, 5]. Colorectal cancer (CRC) survivors are known to experience various symptoms that significantly affect their quality of life (QOL); it is important to identify clinical markers related with CRC survivor QOL. We investigated the relationship between serum chemerin levels, a newly identified proinflammatory adipokine, and QOL in CRC survivors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
